The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for December 2021 (PDF).
This issue reminds clinicians that elderly patients are at an increased risk of adverse neurological and cardiac effects when being treated with haloperidol for delirium. This reminder follows an analysis of Yellow Card Reports. It is recommended that the lowest possible dose of haloperidol should be used for the shortest possible time, and cardiac and extrapyramidal adverse effects should be closely monitored.
This issue also advises that the indication for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus as previously reported.
This issue contains the latest COVID-19 vaccine information including information on the expanded vaccination programme and minor updates to the Summary of Product Characteristics.
Lastly in this issue is a summary of letters to healthcare professionals in November. These generally related to supply issues and recalls.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.